Free Gingival Graft Workflow Template

Free gingival graft.

RMH: Medical history reviewed/updates
Vitals: BP/pulse; other vitals if indicated

Recipient site: Recipient site
Teeth: #Tooth number(s)
Indication: Indication/diagnosis
Inadequate keratinized tissue.
Recession.
Pre-op recession: Pre-op recession
Donor site: Donor site

Consent: Consent/PARQ reviewed; signed/verbally obtained

Anesthesia: Anesthetic used
Carps: Carpules/amount

Graft/defect support: Reason grafting required; defect/recession dimensions; site/tooth
Image support: Radiograph/CBCT/intraoral photo of defect
Material details: Graft/biologic/membrane/suture material and amount
Prognosis/follow-up: Healing expectations and follow-up plan

Procedure:
Recipient bed prepared.
Periosteum exposed.
Graft harvested from palate.
Graft dimensions: Graft dimensions
Graft placed at recipient site.
Graft sutured.
Donor site dressed.
Hemostasis achieved.

Complications: None or describe.

Patient tolerance: Tolerance/response.

Post-op instructions: Instructions reviewed.
Soft diet.
No brushing treated areas.
Rx: Prescription or none

NV: Next visit

Documentation requirements

Mucogingival surgery is a documentation-heavy procedure family because the case turns on tissue dimensions and a defensible biologic indication. Per AAP mucogingival therapy guidance, ADA CDT descriptor language for D4277 / D4275 / D4283,'s periodontics chapter, a defensible FGG note must contain:

• Recipient site — tooth number(s), implant position(s), or edentulous tooth position(s) using universal numbering (e.g., "facial #22-#27" or "facial of implant #19"). Specify the surface (almost always facial; rarely lingual). The "first tooth/implant/edentulous tooth position in graft" rule under D4277 is per contiguous graft; non-contiguous grafts each get their own first-position code.
• Quadrant / region — UR / UL / LR / LL anterior / posterior. Mandibular anterior is the classic recipient site for KT augmentation in thin biotypes.
• Mucogingival diagnosis — inadequate keratinized tissue, mucogingival junction at or coronal to the gingival margin, recession with thin biotype, peri-implant mucositis with inadequate KT, or pre-prosthetic / pre-implant soft-tissue conversion. Reference the Cairo recession type (RT1 / RT2 / RT3) or Miller Class (I-IV) when applicable; AAP/EFP world workshop favors Cairo as the contemporary classification.
• Pre-op KT width and attached gingiva at the recipient site in mm — measured with a periodontal probe from the gingival margin to the mucogingival junction (total KT) and minus the probing depth to derive attached gingiva. The pre-op number is what the post-op gain is measured against and is the single most important defensive measurement.
• Pre-op recession in mm and Miller / Cairo class when recession is present — measured from the cementoenamel junction (or restorative margin / implant platform) to the gingival margin at the mid-facial; record class to communicate root-coverage prognosis. Note that FGG is not the procedure of choice when root coverage is the goal in a Miller I/II case (use CTG); the recession measurement is recorded so the chart shows the FGG indication is KT augmentation, not root coverage.
• Pre-op probing depth, BOP, mobility at the involved teeth — establishes baseline for re-evaluation and rules out concurrent active periodontitis that would change the surgical plan.
• Pre-op intraoral photographs — the single strongest piece of audit evidence on mucogingival cases. Capture the recipient site pre-op (gingiva closed) showing the inadequate KT band, an intra-op photo with the recipient bed prepared and periosteum exposed, an intra-op photo of the harvested graft on a saline-moistened gauze with a ruler/periodontal probe for scale, and a post-suturing photo. Many AAP-trained periodontists routinely capture all four; the checklist explicitly calls for "intraoral photo of mucogingival defect" as part of D4277 support.
• Pre-op imaging when relevant — PA(s) of involved teeth to rule out periapical pathology that would change the staging plan; CBCT is uncommon for an isolated FGG but may be present from the implant work-up the FGG is preparing for. Imaging is not a hard requirement on D4277 the way it is on D4263, but is often present in the chart from adjacent work-up.
• Medical and dental history — reviewed today; flag bisphosphonates / anti-resorptives (MRONJ risk for any oral surgical procedure, including palatal harvest), anticoagulants (palatal donor site is a notable bleeding risk — greater palatine artery), immunosuppression, uncontrolled diabetes (HbA1c), smoking (tobacco impairs free-graft revascularization and is the single largest patient-side predictor of graft necrosis or partial take), and history of head/neck radiation.
• Vitals — pre-op BP and pulse; many state boards and most surgical practices require these on operative visits.
• Informed consent / PARQ — risks specific to FGG: post-op palatal pain (almost universal — set expectations), palatal donor-site bleeding (especially in anticoagulated patients; greater palatine artery zone), graft necrosis or partial take, color/texture mismatch ("tire-patch" appearance) at the recipient site, recession at the donor site (rare), incomplete KT gain requiring repeat surgery, recipient-site failure, sensitivity, alternatives (no treatment with monitoring, non-autogenous allograft / xenograft alternative such as AlloDerm or Mucograft under D4275, CTG when root coverage is the primary goal), no-treatment risks (continued mucogingival pull, progressive recession, peri-implant mucositis, eventual need for more advanced surgery). Note signed vs verbal.
• Anesthesia — agent, concentration, vasoconstrictor, technique. FGG typically requires two sites of anesthesia: recipient (infiltration) and donor (palatal — greater palatine and nasopalatine; sometimes infiltration alone for small grafts). Document carpule count and any block technique.
• Recipient bed preparation — split-thickness (partial-thickness) preparation to expose periosteum while leaving the periosteum intact on the underlying bone. This is the textbook FGG bed (the graft revascularizes from the exposed periosteum). Document the bed dimensions in mm (length x width) and confirmation that periosteum is intact and exposed.
• Donor site selection and harvest — palatal harvest 2-3 mm apical to the palatal gingival margin between the mesial of the first molar and the distal of the canine (the safe zone away from the greater palatine artery and rugae). Tuberosity harvest as alternative for small grafts. Document the donor site explicitly.
• Graft dimensions — length x width x thickness in mm (e.g., "8 mm x 5 mm x 1.5 mm"). The thickness number is what distinguishes a true FGG (full-thickness epithelium + lamina propria, typically 1.0-2.0 mm) from a CTG (sub-epithelial connective tissue only). Record on a saline-moistened gauze photo when possible.
• Donor-site management — primary closure (rare on palate due to tissue character), hemostatic agent (collagen plug, oxidized cellulose, gelatin sponge, PRF membrane), suture pattern, palatal stent / Essix / Coe-Pak placement when used. Donor-site bleeding is the most common acute complication; document the hemostasis plan.
• Graft placement and suturing — graft adapted to the recipient bed with the keratinized epithelium oriented coronally; periosteal anchoring sutures (sling, simple interrupted, or compression sutures) and stabilization sutures (typically 5-0 or 6-0 chromic gut, PTFE, or polypropylene). Document suture material, size, pattern, and count. The graft must be immobile at the end of the case — graft mobility during early healing is the single largest cause of partial take.
• Hemostasis — achieved at both sites; method if notable (pressure, hemostatic agent at donor site, electrosurgery for soft tissue distant from graft).
• Complications — explicit "None" or describe (excessive palatal bleeding, perforation through to nasal floor on tuberosity harvest, graft tearing during harvest, inability to immobilize graft).
• Patient tolerance / response — tolerated well, vitals stable, no adverse events.
• Post-op instructions — soft diet 1-2 weeks, no brushing the recipient site for the prescribed window (typically 2 weeks; chlorhexidine 0.12% rinse BID instead, or saline rinses if the patient cannot tolerate chlorhexidine over the recipient site), no flossing or interdental cleaning at the recipient site, no smoking (heavily emphasized — primary patient-side predictor of failure), no straws / no spitting first 24 h, no spicy or hot foods (palatal donor irritation), expected palatal soreness, ice intermittent first 24 h, return precautions (uncontrolled palatal bleeding, increasing pain after 72 h, fever, suture loss before scheduled removal, graft mobility, complete loss of graft).
• Prescriptions — analgesic regimen (ibuprofen 600 mg q6h prn ± acetaminophen 500 mg alternating per current AAP and ADA pain-control guidance favoring NSAID-first protocols over routine opioids); chlorhexidine 0.12% gluconate rinse BID x 2 weeks; antibiotic per practice protocol — many periodontists do not routinely prescribe antibiotics for an isolated FGG in a healthy patient (literature does not support routine prophylaxis), but practice protocols vary, especially when allograft / xenograft is used or the patient has risk factors. Some practices dispense an analgesic-strength acetaminophen-codeine for the first 24-48 h of palatal pain; document indication if used.
• Re-evaluation plan — soft-tissue check at 1-2 weeks for suture removal (chromic gut resorbs; PTFE removed at 7-14 days); 6-8 week re-evaluation with re-measured KT width and assessment of graft take before next phase (typically implant placement, restorative finalization, or perio re-eval). The 6-8 week interval before the next phase is the AAP-typical healing window for free grafts and is the single most cited timing in published mucogingival surgery sequencing.
• Provider signature and assistant initials.

Three phrases that defuse the most common audit questions: an explicit pre-op KT width and attached gingiva in mm ("pre-op KT 1 mm, attached gingiva 0 mm, mid-facial #23-#26, mucogingival junction at the gingival margin"), the donor and graft dimensions ("palatal donor, harvest 2 mm apical to gingival margin between mesial #14 and distal #11; graft 14 mm x 6 mm x 1.5 mm"), and the planned KT goal with re-evaluation timing ("target KT >3 mm post-op; re-eval 6-8 weeks before implant placement #24"). All three track AAP mucogingival classification and ADA descriptor language directly.

Common denial reasons

D4277 / D4275 carry meaningful dollar exposure and are routinely reviewed. The most frequent reasons FGG-family claims are denied, downgraded, or recouped:

• Missing or weak pre-op KT measurement — chart says "inadequate keratinized tissue" without a number. The single most common denial reason on D4277 review. Reviewers want a specific pre-op KT width and attached gingiva measurement in mm at the recipient site.
• No pre-op intraoral photos — increasingly an expected element on review by major commercial carriers and AAP-style chart audits. The mucogingival defect is photograph-defensible and silence reads as a missed step.
• Donor-site documentation missing or vague — chart says "graft from palate" without dimensions, depth, or hemostasis plan. Some carriers will downgrade D4277 to D4275 (non-autogenous) when the autogenous harvest is not clearly documented.
• Graft dimensions not recorded — length x width x thickness in mm establishes that a true free graft (with epithelium + lamina propria) was harvested. Missing dimensions can be cited as a documentation deficiency.
• D4277 billed for a connective tissue graft (CTG) — that's D4273 (autogenous) or D4275 (non-autogenous). Reviewers cross-check the procedure description against the code: "sub-epithelial connective tissue" = CTG; "full-thickness epithelium + lamina propria" = FGG. Miscoding triggers automatic downgrade or denial.
• D4277 billed for a pedicle / coronally advanced flap without a free graft — that's D4270. FGG requires a separate donor surgical site.
• D4277 billed for vestibuloplasty — that's D7340 / D7350. Different code family when the goal is ridge extension, not KT augmentation.
• Multiple D4277s billed in the same contiguous graft strip — only one D4277 per contiguous graft per session; additional positions bill D4283. Auto-rejected by carrier edits.
• Indication is root coverage on a Miller I/II case in the esthetic zone — reviewers may question why FGG was selected over CTG (which provides better color/texture match and root coverage). Document the KT-augmentation indication explicitly so the chart shows root coverage was not the primary goal.
• D4277 + D4275 same site billed together — some practices bill both attempting to cover both the autogenous harvest and an adjunct dermal matrix; carriers typically pay one or the other, not both, on the same site.
• D4277 + D4263 / D6104 / D7953 same-DOS bundling denials — even when both are clinically indicated, some carriers bundle on automated review. Workaround is a narrative naming the bone-graft sites separately from the soft-tissue graft sites.
• Re-graft at a previously failed site without narrative — most carriers will not pay a second D4277 on the same site without a narrative documenting the failure mode and the clinical rationale.
• Smoker / uncontrolled diabetic without risk-factor narrative — some clinical-policy bulletins flag these patients as higher-risk for graft failure and require an explicit narrative addressing risk before paying.
• Default-template chart notes — identical KT measurements, recession depths, graft dimensions, and suture descriptions across multiple patients flagged as templating. Medicaid MCO and several commercial carriers run template-fingerprint review.
• Failure to schedule or document 6-8 week re-evaluation — the KT-augmentation goal is the indication for the procedure; not following through with re-measurement weakens the chart's defense if the case is later audited.
• Antibiotic prophylaxis prescribed without justification — flagged in chart audits even though it doesn't affect D4277 reimbursement directly. Routine antibiotics for an isolated FGG in a healthy patient are not universally supported by the literature; document the indication when prescribed.